Rezolute announces positive recommendation after independent interim analysis of phase 3 sunrize study of ersodetug in congenital hyperinsulinism (“hi”)

Independent data monitoring committee (the “dmc”) recommends continuation of sunrize trial as planned with no need to increase sample size enrollment on track and expected to be completed in may 2025; topline data anticipated in december 2025 u.s. sites activated and enrolling patients redwood city, calif., april 23, 2025 (globe newswire) --   rezolute, inc.
RZLT Ratings Summary
RZLT Quant Ranking